TFF Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2016 - 2018
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2016 - 2018
Revenue	0.73	0.5	0.09	-	-	Upgrade
Revenue Growth (YoY)	48.02%	462.39%	-	-	-	Upgrade
Cost of Revenue	11.97	18.42	21.26	10.68	-	Upgrade
Gross Profit	-11.24	-17.93	-21.17	-10.68	-	Upgrade
Selling, General & Admin	10.66	13.87	10.62	8.01	3.17	Upgrade
Research & Development	-	-	-	-	8.82	Upgrade
Operating Expenses	10.66	13.87	10.62	8.01	11.99	Upgrade
Operating Income	-21.89	-31.8	-31.79	-18.69	-11.99	Upgrade
Interest & Investment Income	0.27	0.03	0.05	0.13	0.12	Upgrade
Other Non Operating Income (Expenses)	0.39	-	0.7	-	-	Upgrade
Pretax Income	-21.24	-31.77	-31.04	-18.57	-11.87	Upgrade
Net Income	-21.24	-31.77	-31.04	-18.57	-11.87	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	-	24.81	Upgrade
Net Income to Common	-21.24	-31.77	-31.04	-18.57	-36.68	Upgrade
Shares Outstanding (Basic)	2	1	1	1	0	Upgrade
Shares Outstanding (Diluted)	2	1	1	1	0	Upgrade
Shares Change (YoY)	49.48%	20.78%	21.52%	195.80%	98.20%	Upgrade
EPS (Basic)	-11.85	-26.49	-31.26	-22.73	-132.79	Upgrade
EPS (Diluted)	-11.85	-26.49	-31.26	-22.73	-132.79	Upgrade
Free Cash Flow	-16.13	-28.89	-30.43	-17.72	-11.22	Upgrade
Free Cash Flow Per Share	-9.00	-24.09	-30.64	-21.69	-40.61	Upgrade
Operating Margin	-2983.45%	-6413.16%	-36055.24%	-	-	Upgrade
Profit Margin	-2894.68%	-6407.77%	-35206.85%	-	-	Upgrade
Free Cash Flow Margin	-2198.34%	-5827.59%	-34511.26%	-	-	Upgrade
EBITDA	-21.39	-31.41	-31.68	-	-	Upgrade
D&A For EBITDA	0.5	0.39	0.11	-	-	Upgrade
EBIT	-21.89	-31.8	-31.79	-18.69	-11.99	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q